ERBB4 and idiopathic pulmonary fibrosis: This proposition will lay a foundation for the clinical diagnosis and treatment of pulmonary inflammation and M2 activation of pulmonary macrophages and provide a theoretical support for ErbB4 as a new target for the diagnosis and treatment of inflammation and IPF.